AVRO 1330% upside potential according to this analyst!!!
AVROBIO is a clinical-stage gene therapy company to treat rare diseases following a single dose worldwide.
AVRO just released positive data on their Phase 1/2 trial testing the safety and efficacy of AVR-RD-04.
73.42% of the shares are controlled by institutional investors, which gives me a lot of trust in the company.
JPMorgan Chase and BlackRock Inc. have the largest stakes in the company with an average around $9 per share.
On 1/5/2022 Barclays brokerage Boosted the Price Target of AVRO from $6.00 to $22.00.
The stock is now at all time low: $1.65.
the MARKET CAP is only 71.978Mil
I think it can be an easy buyout at this point.
What are we waiting for?
AVRO just released positive data on their Phase 1/2 trial testing the safety and efficacy of AVR-RD-04.
73.42% of the shares are controlled by institutional investors, which gives me a lot of trust in the company.
JPMorgan Chase and BlackRock Inc. have the largest stakes in the company with an average around $9 per share.
On 1/5/2022 Barclays brokerage Boosted the Price Target of AVRO from $6.00 to $22.00.
The stock is now at all time low: $1.65.
the MARKET CAP is only 71.978Mil
I think it can be an easy buyout at this point.
What are we waiting for?
BUYSELL indicators tradingindicators.store/
TRADING COURSE bit.ly/tradex
Private Signals patreon.com/PremiumOptionsSignals
RESULTS bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
TRADING COURSE bit.ly/tradex
Private Signals patreon.com/PremiumOptionsSignals
RESULTS bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.